1. Domestic innovation drug companies are leading the fourth generation of EGFR target-to-drug research and development.
The fourth generation of EGFR targets is becoming a new research and development direction in the field of oncology treatment, mainly targeting the third generation of EGFR-TKI resistance treatment needs. The problem of resistance to medicines has been one of the most common mutations of EGFR targets, with a prevalence...